Ablynx strengthens management team

Appoints Dr Andreas Menrad as chief scientific officer

Dr Andreas Menrad

Belgian biopharmaceutical firm Ablynx has appointed Dr Andreas Menrad as chief scientific officer.

Dr Menrad has more than 20 years’ experience in the pharmaceutical and biotech industry, with significant expertise in drug discovery and the progression of leading drug candidates into pre-clinical development. He will be responsible for the ongoing development of Ablynx’s Nanobody platform and identify and prioritise new therapeutic programmes that will be taken forward either on its own or with partners.

Prior to joining Ablynx, Dr Menrad was at Genzyme for five years, where since 2011 he held the position of general manager and vice president of Antibody Therapeutics. Previously he has also held senior research positions with Schering.

Companies